Unsual Clinical Features Of Miller-Fisher Syndrome: Case Report

10.5580/3c ◽  
2010 ◽  
Vol 12 (2) ◽  
2017 ◽  
Vol 4 (4) ◽  
pp. 1193
Author(s):  
Shubhransu Patro ◽  
Vipin S. ◽  
Pankaj K. Khora ◽  
Payod K. Jena

Miller Fisher Syndrome (MFS) is an uncommon variant of Guillain Barre syndrome (GBS). It is largely a clinical diagnosis based on the cardinal clinical features of ophthalmoplegia, ataxia and areflexia. The following case report is that of a patient who presented with an acute history of reeling of head, difficulty in opening the eyelids and swaying while walking, on clinical examination revealed the above-mentioned cardinal features and on investigation showed positive serum anti GQ1b antibody titer. The patient started recovering with conservative management and was discharged in the recovery phase.


Author(s):  
A. Peral Quirós ◽  
F. Acebrón ◽  
M. del Carmen Blanco Valero ◽  
F. Labella Álvarez

2021 ◽  
Vol 75 (3) ◽  
pp. 234
Author(s):  
Maja Ravlic ◽  
Lana Knezevic ◽  
Iva Krolo ◽  
Jelena Herman

2018 ◽  
Vol 58 (5) ◽  
pp. 746-749
Author(s):  
David Moreno-Ajona ◽  
Pablo Irimia ◽  
Marta Fernández-Matarrubia

2016 ◽  
Vol 2016 ◽  
pp. 1-3 ◽  
Author(s):  
Ioannis E. Dagklis ◽  
Sotirios Papagiannopoulos ◽  
Varvara Theodoridou ◽  
Dimitrios Kazis ◽  
Ourania Argyropoulou ◽  
...  

Miller-Fisher syndrome (MFS) is considered as a variant of the Guillain-Barre syndrome (GBS) and its characteristic clinical features are ophthalmoplegia, ataxia, and areflexia. Typically, it is associated with anti-GQ1b antibodies; however, a significant percentage (>10%) of these patients are seronegative. Here, we report a 67-year-old female patient who presented with the typical clinical features of MFS. Workup revealed antibodies against glutamic acid decarboxylase (GAD) in relatively high titers while GQ1b antibodies were negative. Neurological improvement was observed after intravenous gamma globulin and follow-up examinations showed a continuous clinical amelioration with simultaneous decline of anti-GAD levels which finally returned to normal values. This case indicates that anti-GAD antibodies may be associated with a broader clinical spectrum and future studies in GQ1b-seronegative patients could determine ultimately their clinical and pathogenetic significance in this syndrome.


2020 ◽  
Vol 13 (8) ◽  
pp. e236419 ◽  
Author(s):  
Amanda Ray

Beyond the typical respiratory symptoms and fever associated with severe acute respiratory syndrome, we may still have much to learn about other manifestations of the novel SARS-CoV-2 infection. A patient presented with Guillain-Barré syndrome in China with a concurrent SARS-CoV-2 infection. The following case report looks at a patient presenting with the rare Miller Fisher syndrome, a variant of Guillain-Barré while also testing positive for COVID-19.


2019 ◽  
Vol 48 (3) ◽  
pp. 030006051986749
Author(s):  
Yu-Ming Liu ◽  
Yan-Li Chen ◽  
Yan-Hua Deng ◽  
Yan-Ling Liang ◽  
Wei Li ◽  
...  

Miller Fisher syndrome (MFS), a variant of Guillain–Barré syndrome, is characterized by ataxia, areflexia and ophthalmoplegia. This case report describes a 40-year old male that presented with a 3-day history of unsteady walking and numbness on both hands, and a 2-day history of seeing double images and unclear articulation. Lumbar puncture revealed an opening pressure of 260 mm H2O. Plasma serology was positive for anti-ganglioside M1-immunoglobulin M (anti-GM1-IgM) antibodies and negative for anti-ganglioside Q1b (anti-GQ1b) antibodies. The patient was diagnosed with MFS based on the clinical course and neurophysiological findings. On the 4th day of treatment with intravenous immunoglobulin (IVIG), his ataxia and unsteady walking improved, but his bilateral eyeballs were fixed, and over the next few days he developed bilateral peripheral facial paralysis. After 5 days of IVIG treatment, methylprednisolone treatment was offered and the patient's symptoms gradually improved. Early intracranial hypertension and delayed facial nerve palsy may be atypical presentations of MFS. Anti-GM1-IgM antibodies may be the causative antibodies for MFS. If the IVIG therapy does not stop the progression of the disease, the addition of corticosteroid therapy may be effective. However, the relationship between IgM type, anti-GM1 antibody and MFS remains unclear and requires further research.


2012 ◽  
Vol 29 (6) ◽  
pp. 105-110 ◽  
Author(s):  
Seung Min Lee ◽  
Young Seung Ji ◽  
Chang Woo Lee ◽  
Ju Hyun Jeon ◽  
Jung Ho Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document